Hedge funds have shifted their stance on U.S. healthcare stocks, cutting positions in a sign of growing investor concern as federal health insurance subsidies near their scheduled expiration. For the first time in 14 weeks, these funds sold more healthcare equities than they bought, according to a recent note from Goldman Sachs, reflecting unease about the industry’s near-term prospects amid political uncertainty.
The subsidies at the center of the debate are part of the Affordable Care Act, also known as Obamacare, and were bolstered during the COVID-19 pandemic to make health insurance more affordable for millions of Americans. Those enhanced subsidies are set to expire on December 31, 2025, unless lawmakers intervene. Without action from Congress, many consumers could face sharply higher premiums in 2026, a shift that investors fear could dampen demand for healthcare services and strain provider finances.
President Donald Trump has signalled his administration’s intention to meet with health insurers to discuss ways to bring down costs. This move comes as public frustration grows over rising healthcare expenses, an issue that could play a significant role in the 2026 midterm elections. Analysts say political negotiations over subsidies and insurance pricing are shaping both policy prospects and market expectations.
Goldman Sachs’ report shows hedge funds became net sellers in several segments, particularly healthcare providers, pharmaceutical and biotech firms. These groups saw more selling pressure than buying for the first time in weeks. By contrast, investor appetite remained relatively stronger in niches like life sciences and healthcare technology, where holdings saw net purchases. The broad tilt toward short positions — bets that stock prices will fall — surpassed long positions by more than eight to one, indicating a strong bearish bias among speculators.
This trend in hedge fund behavior occurs against a backdrop of already high healthcare stock valuations compared with historical averages. While funds have held significant healthcare exposure over the past year, this recent repositioning suggests traders see rising political and economic risks outweighing near-term growth prospects. Many expect volatility in share prices if legislative action fails to secure continued subsidies.
Beyond broad sector moves, some mid-sized healthcare-related stocks drew particular short interest. Telehealth provider Him & Hers and scientific instrument maker Bruker were among the top targets for hedge fund bets against price rises in November, according to market tracking data. These companies’ share dynamics illustrate where short sellers believe earnings or demand could weaken under changing policy conditions.
In Congress, policy debates are intensifying. A bill backed by House Republicans and supported by Trump aims to cut insurance premiums for some Americans. However, it would also shrink the overall subsidy pool starting in January 2027, two months after the midterm elections. That timing could have political ramifications and further affect investor sentiment, particularly if markets interpret the policy mix as raising costs for many consumers.
Market watchers note that rising healthcare costs — alongside broader inflation in consumer goods and services — have amplified public discontent. Both political parties are under pressure to find solutions, but the pathway ahead remains uncertain. Investors are closely watching negotiations in Washington because subsidy outcomes will directly influence the industry’s revenue outlook and insurer market dynamics.
For now, hedge fund moves reflect a cautious stance. With rising costs, policy risk and elections on the horizon, many big investors are positioning themselves defensively. As Congress works on legislation in the coming weeks, markets will likely continue to digest the potential impact on healthcare demand, insurance pricing and corporate earnings.
